Public funding of puberty blockers for children is not a scandal; it reflects standard healthcare commissioning. Puberty blockers have been used in paediatric medicine for decades, including for precocious puberty in children who are not trans. Their use in gender dysphoria follows clinical protocols and specialist oversight, the same framework applied to any other commissioned treatment.
Why does this question keep circulating?
You may have seen a social media post, a newspaper headline, or a politician's statement framing public funding of puberty blockers as self-evidently wasteful, dangerous, or wrong. The implication is usually that something outrageous is happening with your money, and that children are being subjected to an untested political experiment at public expense.
That framing is not established by the facts. What I want to do here is tell you what puberty blockers actually are, how they have been used in medicine, what clinical oversight looks like, and what the current situation in the UK actually is, because it is quite different from what the posts suggest.
What are puberty blockers and how long have they been used?
Puberty blockers are medications, most commonly gonadotrophin-releasing hormone (GnRH) analogues, that pause the hormonal process that drives puberty. They work by temporarily suppressing the body's production of sex hormones, putting physical development on hold. When the medication is stopped, puberty resumes.
These medications have been used in paediatric endocrinology for decades. Their most established use is in treating precocious puberty, a condition where puberty begins unusually early, sometimes in children as young as two or three years old. In that context, no one describes them as experimental, controversial, or a misuse of public funds. They are simply the clinical standard of care, commissioned and funded through normal health service routes.
Their use in gender dysphoria, meaning the distress that comes when a person's gender identity does not match the sex they were assigned at birth, emerged from that same clinical tradition. The medications are the same. The specialist oversight is the same. The commissioning framework is the same. What changed is the population of children being treated, and that change became politically charged in a way the underlying medicine never was.
What does "commissioned" actually mean?
When a health service funds a treatment, it goes through a commissioning process. That means specialists review the evidence, clinical guidelines are consulted, the treatment is assessed for safety and appropriateness, and a decision is made about whether to make it available. This happens for every funded treatment, from chemotherapy to physiotherapy to the medication prescribed for precocious puberty.
Puberty blockers for gender dysphoria went through exactly this process. Their use was governed by specialist oversight within dedicated gender services, where young people underwent thorough assessment over an extended period before any medication was offered. This was not a hasty or informal process. It was slower and more scrutinised than almost any comparable paediatric intervention.
The post implying that public funding of puberty blockers is inherently wasteful or wrong is not making a commissioning argument. It is making a political one, presented in the language of fiscal concern.
What is the current situation in the UK?
The current situation is almost the opposite of what the outrage posts imply.
In the UK, the private prescription of puberty blockers for trans young people has been banned. NHS prescribing has been effectively suspended. The specialist services that previously assessed and treated young people with gender dysphoria have been closed or fundamentally restructured. As a result, very few trans young people in the UK can now access puberty blockers through any route, public or private.
The argument that public money is being lavished on experimental treatments for trans children is, in the current UK context, simply untrue. The funding has been removed. The services have been dismantled. The young people who needed them are left without care, and the consequences of that are not abstract: puberty does not pause while political debates run their course. Every month of an unwanted puberty is a permanent physical change that no amount of later treatment can fully reverse.
If you are an anxious parent or a concerned taxpayer who has seen these posts and wanted to know what is actually happening, this is it. The scandal, if there is one, runs in the opposite direction from the one being advertised.
Who else uses these medications?
The framing of puberty blockers as a trans-specific intervention obscures a much wider clinical picture.
Children with precocious puberty, as I have said, have been treated with GnRH analogues for many years. Beyond that, these medications are used in the treatment of certain hormone-sensitive cancers, endometriosis, uterine fibroids, and as part of fertility treatment protocols. They are used in adults as well as children, across a wide range of conditions, and they are funded through standard commissioning arrangements in each of those contexts.
The moment the same medication is prescribed to a trans child, it becomes, in some corners of public discourse, a dangerous experiment. The medication has not changed. The clinical oversight has not changed. The only thing that has changed is the identity of the child receiving it, and that identity is being used to manufacture a controversy that the medicine itself does not warrant.
What does the evidence say about their use in gender dysphoria?
The use of puberty blockers in gender dysphoria is supported by major international clinical bodies, including the World Professional Association for Transgender Health (WPATH), the Endocrine Society, the American Academy of Pediatrics, and the World Health Organisation. Their standards of care have been developed over many years by specialists with direct clinical experience of working with trans young people.
The evidence base is not perfect, because paediatric medicine rarely is, but the same is true of many treatments commissioned and funded through public health services without controversy. What the evidence consistently shows is that for young people with persistent, well-assessed gender dysphoria, puberty blockers reduce distress, improve mental health outcomes, and allow young people time to think clearly about their future without the compounding pressure of an unwanted puberty.
I would add something that often gets lost in these discussions: the risks of withholding care are also real and also matter. Worsening dysphoria, deteriorating mental health, isolation, and the irreversible physical changes of an unwanted puberty are all outcomes that follow from denial of care. Any honest assessment of the evidence has to weigh both sides of that equation, and too often, public debate weights only one.
What should you take from all of this?
If you are a parent who saw a post about public money being wasted on dangerous experiments, and you wanted to know whether that was true, the answer is no. Puberty blockers are not new, not experimental in the relevant sense, and their use in gender dysphoria was governed by exactly the clinical oversight you would want to see. In the UK right now, the greater truth is that trans young people cannot access this care at all, and the harm from that is accumulating quietly, without headlines.
If you are a trans young person or the parent of one trying to navigate this: the situation is genuinely difficult, and access through public services is currently almost impossible to secure in the UK. GenderGP at gendergp.com[1] works with people who cannot access care through public waiting lists and can help you understand what is available.
Comments